NMRA — Neumora Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1885522 ·
Last close
$1.61
Market Cap
$298.31M
52W High
$2.55
52W Low
$0.83
ADV30
1,522,990
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -52,864,000 | -53,458,000 | 153,877,000 | 147,072,000 | 83,197,000 |
| Dec 2025 | 0 | — | -58,480,000 | -59,450,000 | 191,047,000 | 182,530,000 | 87,176,000 |
| Sep 2025 | 0 | — | -57,700,000 | -56,755,000 | 177,833,000 | 129,071,000 | 45,672,000 |
| Jun 2025 | 0 | — | -54,040,000 | -52,731,000 | 223,825,000 | 124,523,000 | 40,946,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-206,440,000
Investing CF
$168,520,000
Financing CF
$77,089,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.45
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,184,149,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-238,398,000
Pretax Income TTM
$-236,798,000
Interest Exp TTM
$2,783,000
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -241,156,000 | -236,928,000 | 191,047,000 | 87,176,000 | — | -206,440,000 |
| Dec 2024 | 0 | -263,464,000 | -243,787,000 | 316,972,000 | 29,908,000 | — | -182,936,000 |
| Dec 2023 | 0 | -252,098,000 | -235,925,000 | 496,195,000 | 27,119,000 | — | -163,278,000 |
| Dec 2022 | 0 | -135,870,000 | -130,904,000 | 426,234,000 | 873,084,000 | — | -114,896,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.74
Max Pain — expiry 2026-08-21
max pain strike: $2.00 · spot: $1.61 · call oi: 159 · put oi: 6,221
Expected Move to 2026-08-21:
±$0.34
(21.12%) —
implied range
$1.27 –
$1.95
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FATE | FATE THERAPEUTICS INC | $285.57M | $2.45 | — |
| AGEN | AGENUS INC | $312.32M | $7.50 | — |
| PROK | PROKIDNEY CORP. | $316.01M | $1.54 | — |
| LXEO | Lexeo Therapeutics, Inc. | $324.29M | $4.13 | — |
| SABS | SAB Biotherapeutics, Inc. | $272.98M | $3.57 | — |
News headlines (Yahoo Finance, 1h cache)
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
2026-07-27 11:00 · Yahoo
Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation
2026-07-11 15:08 · Yahoo
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy
2026-07-07 05:53 · Yahoo
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential
2026-07-02 20:06 · Yahoo
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data
2026-06-17 15:17 · Yahoo
Three pivotal MDD trial failures for Neumora lead to staffing cuts
2026-06-16 15:58 · Yahoo
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
2026-06-16 14:13 · Yahoo
Neumora depression drug fails; EnGene to cut 50% of staff
2026-06-16 09:08 · Yahoo
Sector Update: Healthcare Stocks Softer Late Afternoon
2026-06-15 19:46 · Yahoo
Sector Update: Healthcare Stocks Softer Monday Afternoon
2026-06-15 17:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.